Skip to main content

Current Duke Appointments & Affiliations


Recent Scholarly Works


Correction: McDaniel et al. Personalized Drug Repurposing Screen Identifies Patient-Specific Therapeutic Candidates for Mucopolysaccharidosis Type IIIB. J. Pers. Med. 2026, 16, 369

Journal article Journal of Personalized Medicine · October 1, 2026 There was an error in the original publication [1]. The second MPSIIIB patient fibroblast line, GM01426, was erroneously described as a compound heterozygous genotype. The correct genotype is homozygous for a G>A substitution at nucleotide 457 of the NAGLU ... Full text Cite

Personalized Drug Repurposing Screen Identifies Patient-Specific Therapeutic Candidates for Mucopolysaccharidosis Type IIIB

Journal article Journal of Personalized Medicine · July 1, 2026 Background: Mucopolysaccharidosis type IIIB (MPSIIIB, Sanfilippo syndrome type B) is a rare lysosomal storage disease caused by deficiency of alpha-N-acetylglucosaminidase (NAGLU) enzyme, leading to progressive accumulation of heparan sulfate and severe ne ... Full text Cite

Reversal gene expression assessment for drug repurposing, a case study of glioblastoma.

Journal article J Transl Med · January 7, 2025 BACKGROUND: Glioblastoma (GBM) is a rare brain cancer with an exceptionally high mortality rate, which illustrates the pressing demand for more effective therapeutic options. Despite considerable research efforts on GBM, its underlying biological mechanism ... Full text Link to item Cite
View All Scholarly Works